Entera Bio Ltd. logo
Entera Bio Ltd. ENTX
$ 1.21 -3.97%

Annual report 2020
added 08-19-2023

report update icon

Entera Bio Ltd. Cost of Revenue 2011-2026 | ENTX

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.
What is included in the cost of revenue
Cost CategoryExamples
Production CostsMaterials, wages of production staff, depreciation of equipment
Service and SupportCustomer service, user support, technical assistance
Delivery and LogisticsPackaging, delivery of goods to customers
Hosting and InfrastructureServers, cloud platforms (especially for IT and SaaS companies)
Content and LicensesLicense purchases, production royalties (e.g., in streaming services)

Importance of the Metric
  • Helps to understand how costly the revenue-generating process is.
  • A high cost of revenue may indicate:
    Poor cost control
    Low operational efficiency
  • A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Entera Bio Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 209 K 210 K - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
210 K 209 K 210 K

Quarterly Cost of Revenue Entera Bio Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - 63 K - - - 31 K - - - 62 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
63 K 31 K 52 K

Cost of Revenue of other stocks in the Biotechnology industry

Issuer Cost of Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
32.2 M - 2.43 % $ 254 M germanyGermany
Aquestive Therapeutics Aquestive Therapeutics
AQST
18.6 M $ 4.14 0.36 % $ 443 M usaUSA
Ardelyx Ardelyx
ARDX
39.5 M $ 6.06 1.94 % $ 1.46 B usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
36.7 M $ 23.83 0.85 % $ 3.03 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
20.6 M $ 2.65 -1.12 % $ 16.6 M usaUSA
I-Mab I-Mab
IMAB
27.2 M - - $ 866 M chinaChina
BioCardia BioCardia
BCDA
4 K $ 1.2 -0.04 % $ 8 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
12.3 M $ 9.6 6.37 % $ 1.98 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
926 K - -18.52 % $ 27.3 M britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
15.3 M - -24.86 % $ 820 K usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
91.7 M $ 9.48 -3.27 % $ 613 M usaUSA
BioVie BioVie
BIVI
312 K $ 1.45 2.09 % $ 2.14 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
100 K - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
90 K - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
40 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
145 M - 1.93 % $ 17.4 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
717 M $ 56.49 1.78 % $ 10.8 B usaUSA
BioNTech SE BioNTech SE
BNTX
2.91 B $ 92.3 1.23 % $ 27.2 B germanyGermany
BioXcel Therapeutics BioXcel Therapeutics
BTAI
164 K $ 1.16 -2.12 % $ 14.2 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
5.42 M $ 19.97 2.94 % $ 1.78 B usaUSA
Codexis Codexis
CDXS
9.34 M $ 1.97 7.97 % $ 172 M usaUSA
Cerus Corporation Cerus Corporation
CERS
33.4 M $ 1.91 2.42 % $ 364 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
13.8 M $ 1.75 0.87 % $ 205 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
238 M - - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
12.4 B - - $ 96.9 B britainBritain